Project Grant R01CA303116
Award Date 5/19/26
Completion Date 4/30/31
Dollars Obligated $652K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
- Federal Grant Award Summary The National Cancer Institute awarded The Wistar Institute of Anatomy and Biology a $473,624 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 3, 2026, with a completion date of March 31, 2028. This research project investigates the role of myeloid cell-derived interleukin 1B (IL1B) in promoting chemoresistance in metastatic ovarian cancer, with the goal of developing therapeutic strategies to overcome treatment resistance. The...
- Federal Grant Award Summary The National Cancer Institute awarded The Wistar Institute of Anatomy and Biology a $780,764 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 15, 2026, with completion targeted for March 31, 2031. This research initiative investigates the role of branched-chain amino acid (BCAA) oxidation and signaling pathways in tumor-associated macrophages (TAMs) to enhance anti-tumor immunity in pancreatic ductal adenocarcinoma (PDAC). The...
- Federal Grant Award Summary The National Cancer Institute awarded The Institute For Cancer Research a $483,395 Project Grant under the Cancer Treatment Research program (CFDA 93.395) beginning September 1, 2025, and concluding August 31, 2027. This research initiative focuses on investigating P300 and CBP (Cyclic AMP-Response Element Binding Protein) as novel therapeutic targets in renal cell carcinoma (RCC), specifically clear cell RCC (ccRCC). The project will examine the therapeutic potential...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $399,829 Project Grant to The Washington University on May 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and mechanistically characterize a novel dendritic cell (DC)-based immunotherapy designated AB7H3-TLR4 CAR-DCs. This research will deliver scientific and technical outputs aimed at overcoming tumor immune tolerance in solid tumors by engineering dendritic cells that express a...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $2.47 million under the Cancer Biology Research program (CFDA 93.396) on August 18, 2025, with completion targeted for July 31, 2029. This grant supports fundamental research investigating the role of wild-type isocitrate dehydrogenase 1 (WT-IDH1) metabolism in reprogramming the tumor microenvironment of glioblastoma. The research encompasses both in vitro and in...
- Federal Grant Award Summary The National Cancer Institute awarded The Washington University a $645,185 Project Grant on May 15, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop and validate a novel immunotherapeutic approach for glioblastoma treatment. The grant supports a five-year research initiative (through April 30, 2031) focused on the "Expand and Pull" concept, which combines long-acting interleukin-7 (IL-7) therapy with oncolytic virus treatment to...
- Federal Project Grant Award Summary Massachusetts General Hospital (MGH), through its Research Management Division, received a $707,798 project grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), effective April 1, 2026 through March 31, 2031. The award funds research to determine mechanisms of heterogeneous treatment response in glioblastoma (GBM), an aggressive brain tumor that typically recurs in treatment-refractory form shortly after...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a Project Grant totaling $901,205 to Boston Children's Hospital under the Cancer Treatment Research program (CFDA 93.395) effective July 3, 2025, with a completion date of June 30, 2032. This research initiative focuses on identifying genome-wide changes in gene expression during early tumorigenesis and metastatic progression to improve immunotherapy efficacy. The project leverages genetically engineered mouse models...
- Federal Grant Award Summary The National Cancer Institute awarded a Project Grant of $399,829 to The Washington University (Office of Sponsored Research Services) for the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, through March 31, 2028. This research project focuses on the rational design of next-generation engineered T cells to enhance cancer immunotherapy by addressing the critical limitation of T cell persistence in chimeric antigen receptor (CAR) T cell...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Washington University a Project Grant totaling $3,182,665 (Award Date: September 24, 2025; Completion Date: August 31, 2029) under the Cancer Treatment Research program (CFDA 93.395) to investigate the role of natural killer (NK) cells in immune checkpoint therapy (ICT) of cancer. The research will elucidate the mechanisms by which NK cells constrain the effectiveness of ICT, evaluate the contribution of the NKG2D...